Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mike Partsch
AddedMar 31, 2024
UpdatedMay 31, 2026
Mike Partsch

Mike Partsch

Board Member, Promiss Diagnostics

CrunchbaseLinkedIn

Mike Partsch's Career

Promiss Diagnostics
Promiss Diagnostics

Wauwatosa, WI, US

Board Member· Board
Atrility Medical
Atrility Medical

Madison, WI, US

Board Member· Board
Madison Vaccines
Madison Vaccines

Madison, WI, US

Board Member· Board
Nalu Medical
Nalu Medical

Carlsbad, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mike Partsch's Career

Promiss Diagnostics
Promiss Diagnostics
Seed$400k52017Wauwatosa, WI, US
Board Member· Board

Leadership at Promiss Diagnostics

Jalal SulaimanJalal SulaimanFounder
Lisa AnselminoLisa AnselminoBoard Member
Steven KuemmerleSteven KuemmerleBoard Member

Similar to Promiss Diagnostics

Avant DiagnosticsAvant DiagnosticsScottsdale, AZ, USCancer Diagnosticsest. 2008Avant DiagnosticsScottsdale, AZ, US · est. 2008

Avant Diagnostics: Pioneering large panel biomarker screening for early, pre-symptomatic cancer detection.

Public · $1.3M11
Prompt DiagnosticsPrompt DiagnosticsBaltimore, MD, USDiagnostic TestsPrompt DiagnosticsBaltimore, MD, US

Prompt Diagnostics: Rapid, affordable, and precise biotech firm for easy-to-use diagnostic testing.

Pre-Seed · $600k2
Pharus DiagnosticsPharus DiagnosticsLos Angeles, CA, USCancer Screeningest. 2022Pharus DiagnosticsLos Angeles, CA, US · est. 2022

Innovator in non-invasive liquid biopsy for early cancer screening.

Series A · $11M11
Predictive Health Diagnostics CompanyPredictive Health Diagnostics CompanyIrvine, CA, USDiagnostic Testsest. 2017Predictive Health Diagnostics CompanyIrvine, CA, US · est. 2017

Predictive Health Diagnostics: Transforming data into intelligent, science-driven diagnostic tests.

Series A · $17.3M29
Atrility Medical
Atrility Medical
Series A$4M92017Madison, WI, US
Board Member· Board

Leadership at Atrility Medical

Matthew KnoespelMatthew KnoespelCo-Founder
Phil TerrienPhil TerrienCo-Founder
Dave KaysenDave KaysenCEO
James OlsonJames OlsonCo-Founder
Randal MillsRandal MillsCo-Founder
Nick Von BergenNick Von BergenCo-Founder

Similar to Atrility Medical

AtriomxAtriomxMenlo Park, CA, USMedical Devicesest. 2020AtriomxMenlo Park, CA, US · est. 2020

Atriomx offers non-invasive cardiac arrhythmia solutions using advanced data science for precise patient treatment.

Pre-Seed · $11M6
iRhythmiRhythmSan Francisco, CA, USMedical Devicesest. 2006iRhythmSan Francisco, CA, US · est. 2006

iRhythm Technologies, a San Francisco-based company, develops and distributes cardiac rhythm monitoring devices.

Public · $533.2M1.8k
Altrix MedicalAltrix MedicalCentreville, VA, USMedical Equipmentest. 2013Altrix MedicalCentreville, VA, US · est. 2013

Altrix Medical, founded in 2013, develops online applications and medical equipment to enhance lives.

Pre-Seed · $1.2M3
AtaCor MedicalAtaCor MedicalSan Clemente, CA, USMedical Devicesest. 2014AtaCor MedicalSan Clemente, CA, US · est. 2014

AtaCor Medical Inc.: Innovating cardiac pacing solutions as a leading medical device maker.

Series B · $34M23
Madison Vaccines
Madison Vaccines
Series A$15.8M92012Madison, WI, US
Board Member· Board

Leadership at Madison Vaccines

Paul WeissPaul WeissBoard Member
Michael RichmanMichael RichmanBoard Member
Jeff BaileyJeff BaileyBoard Member
Richard LesniewskiRichard LesniewskiCo-Founder
Douglas McneelDouglas McneelCo-Founder

Similar to Madison Vaccines

MimiVaxMimiVaxBuffalo, NY, USCancer Treatmentest. 2012MimiVaxBuffalo, NY, US · est. 2012

MimiVax: A clinical-stage biotech firm specializing in developing immunotherapeutic vaccines for cancer treatment.

Series B · $16.6M3
UbivacUbivacPortland, OR, USCancer Vaccinesest. 2005UbivacPortland, OR, US · est. 2005

UbiVac: A Portland-based biotech firm specializing in the development of therapeutic cancer vaccines.

Seed · $2.2M11
Irazu OncologyIrazu OncologyBaltimore, MD, USCancer Vaccinesest. 2022Irazu OncologyBaltimore, MD, US · est. 2022

Baltimore-based medical organization pioneering superior cancer vaccine platforms for improved outcomes.

Seed · $2.6M5
EpiVax OncologyEpiVax OncologyProvidence, RI, USCancer Vaccinesest. 2017EpiVax OncologyProvidence, RI, US · est. 2017

EpiVax Oncology: A US-based biotech firm specializing in precision cancer immunotherapy vaccines.

Pre-Seed · $1.5M5
Nalu Medical
Nalu Medical
Series E$180.9M1912014Carlsbad, CA, US
Co-Founder

Leadership at Nalu Medical

Hugo HarrodHugo HarrodBoard Member
Daniel PivonkaDaniel PivonkaCo-Founder
Thomas WestThomas WestCEO
Juliet Tammenoms BakkerJuliet Tammenoms BakkerBoard Member
Lee HartleyLee HartleyCo-Founder
William J. DawsonWilliam J. DawsonBoard Member

Mike Partsch's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Mike Partsch

John PatienceJohn PatienceBoard Member · BiodesixDennis DrislaneDennis DrislaneBoard Member · NavaDermMichael GreeleyMichael GreeleyCo-Founder · Flare Capital PartnersJeremy WilsonJeremy WilsonBoard Member · NowdiagnosticsCharles BooradyCharles BooradyFounder · Health Catalyst Capital